promo_leaderboard Ad
‹ All posts

Major Shareholder Boosts Neimeth Holdings with N448 Million Share Purchase

In a significant move for Neimeth International Pharmaceuticals Plc, major shareholder Clinoscope Services Limited has purchased an additional 74.7 million ordinary shares for approximately N448.36 million. This transaction, executed on November 10, 2026, at a price of N6 per share, was disclosed to the Nigerian Exchange (NGX) on November 13, 2026, highlighting the ongoing investment activity by insiders in the company.

The acquisition comes at a pivotal time for Neimeth, which has recently returned to profitability after a challenging financial year in 2024. The company reported a pre-tax profit of N1.49 billion for the year ending December 31, 2025, a remarkable turnaround from a pre-tax loss of N854.43 million the previous year. This recovery was largely driven by a 64% increase in revenue, primarily from its pharmaceutical segment. Despite these positive indicators, Neimeth still grapples with high external debt and liquidity issues, which could affect its future growth trajectory.

Looking ahead, investors will be keen to monitor Neimeth's strategic plans, including a recently approved N50 billion fundraising mandate aimed at supporting expansion efforts, such as building a new manufacturing plant in South-East Nigeria. As the pharmaceutical sector continues to evolve, Neimeth's ability to leverage this capital for growth and innovation could have broader implications for the African market, especially as other companies in the region look to attract investment and enhance their operational capabilities.